APA (7th ed.) Citation

Maurits F. J. M. Vissers, Jules A. A. C. Heuberger, Geert Jan Groeneveld, Jerome Oude Nijhuis, Peter Paul De Deyn, Salah Hadi, . . . Carole Ho. (2022). Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo‐controlled, double‐blind phase I/Ib studies in healthy subjects and patients. Wiley.

Chicago Style (17th ed.) Citation

Maurits F. J. M. Vissers, et al. Safety, Pharmacokinetics and Target Engagement of Novel RIPK1 Inhibitor SAR443060 (DNL747) for Neurodegenerative Disorders: Randomized, Placebo‐controlled, Double‐blind Phase I/Ib Studies in Healthy Subjects and Patients. Wiley, 2022.

MLA (9th ed.) Citation

Maurits F. J. M. Vissers, et al. Safety, Pharmacokinetics and Target Engagement of Novel RIPK1 Inhibitor SAR443060 (DNL747) for Neurodegenerative Disorders: Randomized, Placebo‐controlled, Double‐blind Phase I/Ib Studies in Healthy Subjects and Patients. Wiley, 2022.